Pfizer PFE

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Barron's sees two good fits for Pfizer

      Headlines

      Mon, 15 Sep 2014

      AstraZeneca ( AZN +0.7% ) remains a solid target for Pfizer ( PFE +0.9% ) citing the tax inversion appeal, the ability ..... compelling target due to its lower risk and good fit with Pfizer 's Global Established Product unit while offering the

    2. From Barron’s, September 15, 2014 (Part 1)

      Commentary

      Sat, 13 Sep 2014

      conference on Wednesday. The QE is ending in October, but when will be the first rate hike? Mid-2015? March 2015? Pfizer [ PFE ; -10% since spring; P/E 13; 3.5% yield] is now attractive. Starbucks [ SBUX ; +50% over 2 years; fwd

    3. UPDATE 1- Pfizer , Ranbaxy win dismissal of lawsuit over generic Lipitor

      Headlines

      Fri, 12 Sep 2014

      Sept 12 (Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

    4. UPDATE 1- Pfizer , Ranbaxy win dismissal of lawsuit over generic Lipitor

      Headlines

      Fri, 12 Sep 2014

      Sept 12 (Reuters) - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.

    5. BRIEF- Pfizer , Ranbaxy win dismissal of lawsuit by "direct purchaser" plaintiffs over generic Lipitor

      Headlines

      Fri, 12 Sep 2014

      Sept 12 (Reuters) - * U.S. judges grants Pfizer Inc Ranbaxy Laboratories Ltd

    6. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Thu, 11 Sep 2014

      slightly contribute to bottom-line growth; Amgen's adjusted operating margin should benefit in 2014 and 2017 as the Pfizer collaboration on Enbrel winds down in steps, and we see margin improvement from 38% in 2013 to 43% in 2018. We now

    7. Pfizer ( PFE ) Presents at Morgan Stanley Healthcare Conference (Transcript)

      Headlines

      Wed, 10 Sep 2014

      By SA Transcripts : Pfizer Inc. (NYSE: PFE ) Morgan Stanley Healthcare Conference ..... It’s my pleasure to welcome Pfizer . I first need to refer you to disclaimers ..... President and General Manager of Pfizer Specialty Care and Oncology Units

    8. Riding Merck: The Conservative Aggressive Pharmaceutical Stock Of The Year

      Headlines

      Tue, 9 Sep 2014

      investors. Compared to its big pharma peers YTD, Merck has dominated. GlaxoSmithKline (NYSE: GSK ) is down 10%, Pfizer (NYSE: PFE ) is down 3.5%, J&J (NYSE: JNJ ) is up 13%, Novartis (NYSE: NVS ) is up 16%, and MRK is up a whopping

    9. Merck Vs. Pfizer : Merck Better Performer, Pfizer Better Risk-Reward

      Headlines

      Tue, 9 Sep 2014

      year-to-date as of Friday, 9/5/14, vs. Pfizer 's (NYSE: PFE ) decline of 3%, the answer might look easy to some ..... erosion thanks to patent expirations on major products ( Pfizer 's Lipitor and Merck's Singulair, which was 12

    10. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Tue, 9 Sep 2014

      Ramon Alaix has been president of the Pfizer Animal Health business since 2006 ..... of Zoetis. Under his leadership, Pfizer 's animal health unit successfully ..... president of Central/Southern Europe for Pfizer 's pharmaceutical division. We believe

    « Prev12345Next »
    Content Partners